KRYS - Krystal Biotech: Institutional Ownership Is Swelling
Overview Of Krystal Biotech
I first introduced Krystal Biotech (KRYS) as a long idea several months ago after they released compelling data in dystrophic epidermolysis bullosa (DEB). After doing a deep dive, I published a more lengthy research piece explaining why I believed this company to be one of the most underlooked gene therapy plays on the market. For those who are unfamiliar, their claim to fame is a wholly owned dermatological gene therapy platform based on a proprietary HSV-1 viral vector. In laymen terms, they have the ability to deliver nearly any